Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sean M Devlin

Showing results (121-130 of 174) with videos related to

Pageof 18
Sort By:
Transplantation and Cellular Therapy|July 7, 2024
Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With LymphomaRachel Lorenc, Roni Shouval, Jessica R Flynn, et al.
Haematologica|November 21, 2024
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapyAlexander P Boardman, Victoria Gutgarts, Jessica Flynn, et al.
American Journal of Hematology|March 4, 2021
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m<sup>2</sup> ) in combination with lenalidomide and dexamethasoneNeha Korde, Donna Mastey, Elizabet Tavitian, et al.
British Journal of Haematology|July 1, 2025
Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experienceGiulio Cassanello, Efrat Luttwak, Samantha Brown, et al.
Bone Marrow Transplantation|February 1, 2025
Treatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphomaMagdalena Corona, Andrew Ip, Samantha Brown, et al.
Leukemia|June 20, 2020
Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulinIoannis Politikos, Sean M Devlin, Maria E Arcila, et al.
Blood Advances|June 11, 2024
CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomasGustav Y Cederquist, Javin Schefflein, Sean M Devlin, et al.
Hemasphere|December 1, 2025
Patterns and safety of glucocorticosteroid use following CD19 CAR-T therapy for large B-cell lymphomaEfrat Luttwak, David Nemirovsky, Sean M Devlin, et al.
Blood Cancer Discovery|November 15, 2021
Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic MalignanciesDavid J Chung, Gunjan L Shah, Sean M Devlin, et al.
Blood Advances|August 25, 2021
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cellsMartina Pennisi, Miriam Sanchez-Escamilla, Jessica R Flynn, et al.
Pageof 18

Showing results (121-130 of 174) with videos related to

Sort By:
Pageof 18
Transplantation and Cellular Therapy|July 7, 2024
Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With LymphomaRachel Lorenc, Roni Shouval, Jessica R Flynn, et al.
Haematologica|November 21, 2024
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapyAlexander P Boardman, Victoria Gutgarts, Jessica Flynn, et al.
American Journal of Hematology|March 4, 2021
Tailored treatment to MRD response: A phase I/II study for newly diagnosed multiple myeloma patients using high dose twice-weekly carfilzomib (45 and 56 mg/m<sup>2</sup> ) in combination with lenalidomide and dexamethasoneNeha Korde, Donna Mastey, Elizabet Tavitian, et al.
British Journal of Haematology|July 1, 2025
Outcomes of CD19 CAR-T therapy in central nervous system lymphoma: Insights from a multicentre experienceGiulio Cassanello, Efrat Luttwak, Samantha Brown, et al.
Bone Marrow Transplantation|February 1, 2025
Treatment failure patterns in early versus late introduction of CAR T-cell therapy in large B-cell lymphomaMagdalena Corona, Andrew Ip, Samantha Brown, et al.
Leukemia|June 20, 2020
Engraftment kinetics after transplantation of double unit cord blood grafts combined with haplo-identical CD34+ cells without antithymocyte globulinIoannis Politikos, Sean M Devlin, Maria E Arcila, et al.
Blood Advances|June 11, 2024
CNS bridging radiotherapy achieves rapid cytoreduction before CAR T-cell therapy for aggressive B-cell lymphomasGustav Y Cederquist, Javin Schefflein, Sean M Devlin, et al.
Hemasphere|December 1, 2025
Patterns and safety of glucocorticosteroid use following CD19 CAR-T therapy for large B-cell lymphomaEfrat Luttwak, David Nemirovsky, Sean M Devlin, et al.
Blood Cancer Discovery|November 15, 2021
Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic MalignanciesDavid J Chung, Gunjan L Shah, Sean M Devlin, et al.
Blood Advances|August 25, 2021
Modified EASIX predicts severe cytokine release syndrome and neurotoxicity after chimeric antigen receptor T cellsMartina Pennisi, Miriam Sanchez-Escamilla, Jessica R Flynn, et al.
Pageof 18